Launched in China/Overseas or Under Marketing Application Review

Designated Asia-Pacific Regions
Designated Asia-Pacific Regions
Designated Asian Regions
Designated Asian Regions
Mainland China, HK SAR, Macau SAR and Taiwan
Mainland China, Hong Kong, Macau and Taiwan
China
China
Overseas
Overseas

Product Rights Authorized Region* Indication Clinical Trial Approval Clinical Trial for Registration Marketing Application Marketed Major Marketed Regions*
CN US EU JP
Diazepam Nasal Spray China
EU
For the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e. seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 6 years of age and older

2023.6
For the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e. seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 2-5 years of age
Tildrakizumab Injection
(Biological Agent)
China For the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy

2023.5
Methotrexate Injection 中国 Severe recalcitrant disabling psoriasis, which is not adequately responsive to other forms of therapy such as phototherapy, PUVA, and retinoids

2023.3
Active rheumatoid arthritis in adult patients

2024.7
Methylthioninium Chloride Enteric-coated Sustained-release Tablets China
EU
A diagnostic agent to enhance visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy

2024.6
Ruxolitinib
cream
China
EU
Topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older
Marketing Approval in Macau (2024.4)
and HK (2024.11)
Topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable
Desidustat Tablets China For treating anaemia in non-dialysis adult, Chronic Kidney Disease (CKD) patients
Cyclosporine Eye Drops 0.09% China Increasing tear secretion in patients with keratoconjunctivitis sicca (dry eye)
Latanoprost Eye Drops China Reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
ZUNVEYL oz** For treating mild to moderate dementia of the Alzheimer’s type in adults
Levetiracetam XR Tablet China Adjunctive therapy for the treatment of partial-onset seizures
BCG for Intravesical Instillation
(Biological Agent)
China*** Non-invasive urothelial bladder carcinoma, including curative treatment of carcinoma in situ and prophylactic treatment of recurrence

* Major Marketed Regions indicate where products are approved. CMS’s rights are stated by Rights Authorized Region. CMS has NO development, commercialization or other product rights in unauthorized regions.
** The rights authorized region of ZUNVEYL includes Asia (excluding Japan and the Middle East region) and other designated territories.
*** Taiwan Region is not included in the rights authorized region of BCG for Intravesical Instillation.
Please refer to local prescribing information for more information, including full safety information, on CMS’s marketed medicines, or on medicines marketed by CMS’s collaboration partners.
Updated as at 19 August 2025

Under R&D Stages

Global
Global
Designated Asian Regions
Designated Asian Regions
Mainland China, HK SAR, Macau SAR and Taiwan
Mainland China, Hong Kong, Macau and Taiwan
China
China
Overseas
Overseas

Product Rights Authorized Region* Indication Pre-clinical Clinical Trial Approval Phase I Phase II Phase III Marketing Application*
SDN – 037 China Eye pain and inflammation after cataract surgery
PDP – 716 China Reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
CF101 China Psoriasis
povorcitinib China
Designated Asian Regions
Non-segmental vitiligo, Hidradenitis suppurativa, Prurigo nodularis
Asthma, Chronic spontaneous urticaria
CF102 China Hepatocellular carcinoma
Non-alcoholic fatty liver disease / non-alcoholic steatohepatitis
XF – 73 China
Designated Asian Regions
Prevention of post-surgical staphylococcal infections
Y-3 for Injection China** Used to alleviate neurological symptoms and dysfunction of daily activities caused by acute ischemic stroke
ABP-671 China** Gout
Anti-IL-4Rα Humanized Monoclonal Antibody Injection (MG-K10) China
Designated Asian Regions
Atopic Dermatitis, Asthma, Prurigo Nodularis
Seasonal Allergic Rhinitis
Eosinophilic Esophagitis, Chronic Rhinosinusitis with Nasal Polyps
VEGFA/ANG2 Tetravalent Bispecific Antibody
(Biological Agent)
Global Intended for ocular fundus neovascular diseases
TYK2 Inhibitor
(CMS-D001)
Global Intended for psoriasis
Intended for atopic dermatitis
GnRH Receptor Antagonist
(CMS-D002)
Global Intended for the treatment of moderate to severe pain associated with endometriosis
GLP-1R/GCGR Dual Agonist
(CMS-D005)
Global Intended for obesity/overweight
Cardiac Myosin Inhibitor
(CMS-D003)
Global Intended for hypertrophic cardiomyopathy
~15 Self-developed Innovative Drugs Global

* CMS’s rights are stated by Rights Authorized Region. CMS has NO development, commercialization or other product rights in unauthorized regions.
** Taiwan Region is not included in the rights authorized region.
Please refer to local prescribing information for more information, including full safety information, on CMS’s marketed medicines, or on medicines marketed by CMS’s collaboration partners.
Updated as at 19 August 2025